Motoko Tanaka
Overview
Explore the profile of Motoko Tanaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saito H, Sakai K, Tanaka M, Konomura K, Suzuki M, Tajima G, et al.
Eur J Pediatr
. 2025 Jan;
184(1):123.
PMID: 39779497
Purpose: This systematic review analyzes economic evaluations of newborn screening for congenital cytomegalovirus (cCMV) infection to identify key factors influencing cost-effectiveness and differences in methodological approaches. Methods: Following a pre-registered...
2.
Tokumaru K, Imafuku T, Satoh T, Inazumi T, Hirashima S, Nishinoiri A, et al.
Kidney360
. 2024 Sep;
5(10):1422-1434.
PMID: 39259608
No abstract available.
3.
Shono A, Hoshi S, Koshida R, Tanaka M, Kondo M
Yakugaku Zasshi
. 2024 Jun;
144(7):749-754.
PMID: 38945849
In Japan, influenza vaccination is offered to children and pregnant women at clinics or hospitals as an elective, self-funded treatment, as the vaccination is not included in the national vaccination...
4.
Tanaka M, Okubo R, Hoshi S, Kondo M
Vaccine
. 2024 Feb;
42(8):2081-2088.
PMID: 38418340
Introduction: In Japan, the introduction of a fifth diphtheria-tetanus-acellular pertussis (DTaP) vaccination has been considered, and adolescents aged 11-12 years old who are currently receiving the diphtheria-tetanus (DT) vaccine are...
5.
Suto M, Sugiyama T, Imai K, Furuno T, Hosozawa M, Ichinose Y, et al.
JMA J
. 2023 Aug;
6(3):233-245.
PMID: 37560376
Background: Health insurance claims data are used in various research fields; however, an overview on how they are used in healthcare research is scarce in Japan. Therefore, we conducted a...
6.
Arimura N, Watanabe H, Kato H, Imafuku T, Nakano T, Sueyoshi M, et al.
Toxins (Basel)
. 2023 Mar;
15(3).
PMID: 36977070
Fat atrophy and adipose tissue inflammation can cause the pathogenesis of metabolic symptoms in chronic kidney disease (CKD). During CKD, the serum levels of advanced oxidation protein products (AOPPs) are...
7.
Imafuku T, Watanabe H, Satoh T, Matsuzaka T, Inazumi T, Kato H, et al.
Kidney360
. 2022 Apr;
1(8):781-796.
PMID: 35372949
Background: Renal proximal tubulopathy plays a crucial role in kidney disease, but its molecular mechanism is incompletely understood. Because proximal tubular cells consume a lot of energy during reabsorption, the...
8.
Fujimura R, Watanabe H, Nishida K, Fujiwara Y, Koga T, Bi J, et al.
Kidney360
. 2022 Apr;
1(5):343-353.
PMID: 35369369
Background: Recent clinical studies have shown that proteinuria is a critical factor in the progression of CKD and onset of cardiovascular disease. Inflammation and infiltration of macrophages into renal tissue...
9.
Tanaka M, Okubo R, Hoshi S, Ishikawa N, Kondo M
Vaccine
. 2022 Jan;
40(7):1010-1018.
PMID: 35039195
Introduction: Japan currently recommends four doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in its routine vaccination program, but the introduction of a fifth dose is currently under consideration. An objective...
10.
Ikeda N, Wada H, Ichikawa Y, Ezaki M, Tanaka M, Hiromori S, et al.
Clin Appl Thromb Hemost
. 2022 Jan;
28:10760296211070584.
PMID: 34994210
Introduction: Although D-dimer is a useful biomarker of thrombosis, there are many D-dimer kits, with high and low fibrinogen and fibrin degradation products (FDP)/ D-dimer ratios. Methods: Plasma D-dimer levels...